HC Wainwright & Co. Downgrades Pacira BioSciences to Neutral, Lowers Price Target to $36.5
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsDowngradesPrice Target
HC Wainwright & Co. analyst Douglas Tsao downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Neutral and lowers the price target from $38 to $36.5.
HC Wainwright & Co. analyst Douglas Tsao downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Neutral and lowers the price target from $38 to $36.5.